Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Withdrawn1

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

withdrawn133%

terminated133%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT03082300

completedphase_1

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02113813

withdrawnphase_1

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

NCT02674555

Clinical Trials (3)

Showing 3 of 3 trials

NCT03082300Phase 1

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Terminated

NCT02113813Phase 1

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Completed

NCT02674555Phase 1

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3